Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| NovoSeven® resolved 96.5% of bleeds when initiated within one hour after bleed onset in people with haemophilia A or B with inhibitors | |||||||||||||||||||||||||||||||||||
| By: Nasdaq / GlobeNewswire - 03 Dec 2016 | Back to overview list |
||||||||||||||||||||||||||||||||||
Bagsværd, Denmark, 3 December 2016 - Novo Nordisk today announced that NovoSeven ® (rFVIIa), a portable room temperature stable recombinant activated factor VIIa, resolved 96.5% of bleeds when initiated within one hour after onset of bleeding, demonstrating efficacy of early treatment in people with haemophilia A or B with inhibitors. 1 Efficacy also remained high for bleeds treated after 4 hours. 1 A subanalysis of the SMART-7(TM) study, evaluating the efficacy of NovoSeven ® in a real-world setting, was presented today at the 58 th American Society of Haematology (ASH) annual meeting. Further information
References
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Novo Nordisk A/S via GlobeNewswire
HUG#2061378
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
 | Back to overview list | ||||||||||||||||||||||||||||||||||